Global Industry Analysts, Inc., Oct 2011, Pages: 897
to drive cancertherapy market in the future. Currently approved combinationtherapies include paclitaxel, and carboplatin together with Avastin indicated for the treatment of non-small cell lung cancer
Decision Resources, Inc., Dec 2009, Pages: 38
that are developing targeted therapies?
- Decision Resources analysts weighed in with their insights on the current status and future directions of targeted cancertherapies. What is limiting the commercial potential
Global Industry Analysts, Inc., Sep 2011, Pages: 617
for Apoptosis 10
Apoptosis: The Key to Cutting Edge Cancer Treatment/Therapies 10
Table 6: Apoptosis R&D in Cancer Treatment (2010):
Percentage Share
